---
title: "Bayesian Clinical Trials"
subtitle: Real data case study
output:
  beamer_presentation: 
    keep_tex: true
---

## Case Study (Chiappella et al, 2013)
* Primary endpoint: to determine the maximum tolerated dose (MTD) of lenalidomide given in combination with fixed doses of R-CHOP in elderly patients with untreated DLBCL.

<center>![Figure 1](images/figure1.jpg)<center>

## Case Study (Chiappella et al, 2013)

* $d_{start}$ = 10 mg/day
* DLT definition: the maximum dose inducing any grade $\ge 3$ non-hematologic toxicity or a delay >15 days of a planned cycle date observed during the first two cycles
* TTL=33%

* dose levels: 5, _10_, 15, 20 mg/day
* CRM
* cohort size: 3

## CRM 
One parameter logistic model
$$ 
P\left(Y=1|x_{i}\right)=\psi\left(x_{i},\theta\right)=\frac{exp\left(a_{0}+\theta x_{i}\right)}{1+exp\left(a_{0}+\theta x_{i}\right)}
$$
where 

* $Y_{j}$ is the binary variable indicating toxicity for the $j-th$ patient
* $x_{i}=\psi^{-1}\left(p_{i},\theta\right)$ is the standardized dose level
* $p_{i}$ the initial guesses of toxicity probability (i.e. $p_{1}$=0.15, $p_{2}$=0.20, $p_{3}$=0.25, and $p_{4}$=0.30)
* $a_{0}$ is the intercept 
* $\theta$ is to be estimated. 

## Steps
* choose a prior $\pi\left(\theta\right)$ for $\theta$
* starting from $d_{start}$, compute sequentially, every after _c_ patients (i.e. 3), the Bayesian posterior mean of the model parameter, $\tilde{\theta_{j}}$ as 

$$
E\left(\theta_{j}|data\right)=\int_0^\infty \theta f\left(\theta|data\right) d\theta
$$
where $f\left(\theta|data\right)$ is the posterior density:  

$$
f\left(\theta|data\right)=\frac{L_{j}\left(\theta\right)\pi\left(\theta\right)}{\int_0^\infty L_{j}\left(u\right)\pi\left(u\right) du}
$$

## Steps
* compute $\psi\left(x_{i},\tilde{\theta}_{c}\right)$ and the next 3 patients will be assigned to the (standardized) dose level, that minimizes the distance $$\left|\psi\left(x_{i},\tilde{\theta}_{c}\right)-TTL\right|$$
* after inclusion of _m_ patients, the estimated probability of toxicity for the recommended dose level (at that point!), $x_{R}$, will be $\tilde{P}_{R|m}=\psi\left(x_{R},\tilde{\theta}_{m}\right)$
* a 1-$\alpha$ credibility interval for $P_{R|m}$ is $\left(\theta_{min};\theta_{max}\right)$ where  
$$ 
\int_{\theta_{min}}^{\theta_{max}} f\left(\theta|data\right) d\theta=1-\alpha 
$$
* stop when the maximum sample size has been reached (i.e. _n_=24) or stopping rules have been fulfilled

## Stopping rules (Zohar & Chevret, 2001)
Rules based on posterior distribution
$$
\begin{align}
          & w_{1} = P\left[ \psi\left(x_{first},\tilde{\theta} \right)>TTL|data \right] \\
          & w_{2} = P\left[ \psi\left(x_{last},\tilde{\theta} \right)<TTL|data \right] 
\end{align}
$$

$=>$ stop for wrong dose scale if $w_{1}>0.9$ or $w_{2}>0.9$ 

## Stopping rules (Zohar & Chevret, 2001)
Rules based on predictive distribution of _z_ future responses
$$
\begin{align}
          & w_{3} = \tilde{P}\left[ X\left(j+1\right)=...X\left(j+z\right)|data \right] \\
          & w_{4} = \sum_{y_{1}=0}^{1}...\sum_{y_{z}=0}^{1}\left|\tilde{P}_{R|_{j+z}}-\tilde{P}_{R|_{j+1}}\right|P\left(Y_{j+1}=y_{1},...,Y_{j+z}=y_{z} |data \right) \\
          & w_{5} = \max_\left(y_{1},...,y_{z}\right)  \left|\tilde{P}_{R|_{j+z}}-\tilde{P}_{R|_{j+1}}\right| 
\end{align}
$$

$=>$ stop for futility if $w_{3}>0.9$ 

$=>$ stop for no mean predictive or no maximal predictive gain in point estimate of the estimated probability of toxicity if  $w_{4}<0.05$ or $w_{5}<0.05$, respectively

*****
$$
\begin{align}
          & w_{6} = \sum_{y_{1}=0}^{1}..\sum_{y_{z}=0}^{1}\left|c_{\alpha,j+z}\left(P_{R}\right)-c_{\alpha,j+1}\left(P_{R}\right)\right|P\left(Y_{j+1}=y_{1},..,Y_{j+z}=y_{z} |data \right) \\
          & w_{7} = \max_\left(y_{1},...,y_{z}\right)\left| c_{\alpha,j+z}\left(P_{R}\right)-c_{\alpha,j+1}\left(P_{R}\right)\right|
\end{align}
$$
where $c_{\alpha,.}\left(P_{R}\right)$ is the width of the 100(1-$\alpha$) credibility interval of the toxicity probability at the recommended dose level $d_{R}$.


$=>$ stop for no gain in accuracy of the estimated probability of toxicity if $w_{6}<0.05$ or $w_{7}<0.05$


## Data
| Cohort | Administered dose | Toxicity | dose 5 mg/day | dose 10 mg/day | dose 15 mg/day | dose 20 mg/day |
| ------ | ----------------- | -------- | ------------- | -------------- | -------------- | -------------- |
| 1      | 10                | (0,0,0)  |               |                |                |                |
| 2      | 20                | (1,1,0)  |               |                |                |                |
| 3      | 15                | (0,0,1)  |               |                |                |                |
| 4      | 15                | (1,0,0)  |               |                |                |                |
| 5      | 15                | (1,1,0)  |               |                |                |                |
| 6      | 10                | (0,0,1)  |               |                |                |                |
| 7      | 10                | (0,0,0)  |               |                |                |                |

## bcrm package
bcrm implements a Bayesian CRM (O'Quigley et al, 1990) and can run interactively, allowing the user to enter outcomes after each cohort has been recruited.
```{r, eval=F}
library(bcrm)
```
* Binary toxicity outcome 
* Dose-toxicity models: Hyperbolic Tangent, Logistic (1-and 2-parameter) and Power
* Priors: Gamma, Uniform, Lognormal and Bivariate Lognormal
* Stopping rules: maximum sample size, minimum sample size in conjuction with precision of the MTD or maximum number treated ad MTD

## R code

```{r,eval=F}
dose = c(5, 10, 15, 20)
p.tox0 = c(0.15, 0.20, 0.25, 0.3)
data = data.frame(patient=1:3, dose=rep(2,3), tox=rep(0,3))
target.tox = 0.33
bcrm(stop = list(nmax=24, precision=c(0.16,0.6)), 
     data = data, 
     p.tox0 = p.tox0, 
     dose = dose, 
     ff = "logit1",
     prior.alpha = list(3, a=1, b=0.75),
     target.tox = target.tox,
     sdose.calculate = "mean",
     constrain = FALSE
     )
```

## References
* Chiappella A, Tucci A, Castellino A et al. Lenalidomide plus cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab is safe and effective in untreated, elderly patients with diffuse large B-cell lymphoma: a phase I study by the Fondazione Italiana Linfomi. Haematologica 2013; 98(11): 1732-1738.

* Zohar S, Chevret S. The continual reassessment method: comparison of Bayesian stopping rules for dose-ranging studies. Stat Med 2001; 20: 2827-2843.

* O'Quigley J, Pepe M, Fisher L. Continual reassessment method: a practical design for phase I clinical trials in cancer. Biometrics 1990; 46: 33-48.






